Ryan Spencer Net Worth

The estimated Net Worth of Ryan Spencer is at least $4.05 Миллион dollars as of 10 February 2024. Mr Spencer owns over 20,833 units of Dynavax Technologies stock worth over $2,316,324 and over the last 5 years he sold DVAX stock worth over $877,620. In addition, he makes $859,990 as CEO & Director at Dynavax Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Spencer DVAX stock SEC Form 4 insiders trading

Mr has made over 9 trades of the Dynavax Technologies stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 20,833 units of DVAX stock worth $227,288 on 10 February 2024.

The largest trade he's ever made was exercising 89,250 units of Dynavax Technologies stock on 10 February 2022 worth over $973,718. On average, Mr trades about 20,149 units every 81 days since 2019. As of 10 February 2024 he still owns at least 212,312 units of Dynavax Technologies stock.

You can see the complete history of Mr Spencer stock trades at the bottom of the page.

Mr. Ryan Spencer biography

Ryan Spencer is the CEO & Director at Dynavax Technologies.

What is the salary of Mr Spencer?

As the CEO & Director of Dynavax Technologies, the total compensation of Mr Spencer at Dynavax Technologies is $859,990. There are no executives at Dynavax Technologies getting paid more.

How old is Mr Spencer?

Mr Spencer is 43, he's been the CEO & Director of Dynavax Technologies since . There are 4 older and 1 younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies Corp. is Michael S. Ostrach, 69, who is the Advisor.

What's Mr Spencer's mailing address?

Ryan's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, STE 101, SAN DIEGO, CA, 92121.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... и James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.

What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Complete history of Mr Spencer stock trades at Cidara Therapeutics Inc и Dynavax Technologies

Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include:

• Ryan Spencer,
  CEO & Director
• David F. Novack,
  Pres & COO
• Dr. Robert Janssen,
  Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
• Michael S. Ostrach,
  Advisor
• John Slebir,
  Sr. VP & Gen. Counsel
• Nicole Arndt,
  Sr. Mang. of Investor Relations
• Meg Smith,
  VP Sales & Operations
• Steven N. Gersten,
  Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec.
• Heather Rowe,
  VP of Investor Relations & Corp. Communications
• Jeff P. Coon,
  Sr. VP of HR & Admin.
• Justin Burgess,
  Principal Accounting Officer & Controller
• Kelly MacDonald,
  Sr. VP & CFO
• Laura Brege,
  Director
• Eddie Gray,
  CEO and Director
• Arnold L Oronsky,
  Director
• Stanley A Plotkin,
  Director
• Daniel L Kisner,
  
• Dennis Carson,
  Director
• Natale S Ricciardi,
  Director
• David Louis Johnson,
  Vice President
• Michael S Ostrach,
  Senior Vice President
• Elaine D Sun,
  
• Francis Cano,
  
• Peter R. Paradiso,
  
• Peggy V Phillips,
  
• Brent Mac Gregor,
  
• Julia Marie Eastland,
  
• Scott Dunseth Myers,
  
• Partners L P/Ilbiotechnolog...,
  
• Nest Gary A Van,
  Vice President
• Dino Dina,
  President and CEO
• Denise Gilbert,
  Director
• Martin E Sanders,
  EVP, Chief Development Officer
• James Edeerfield Capital Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Deborah A Smeltzer,
  VP Operations & CFO
• Timothy G Henn,
  Vice President
• Zbigniew Janowicz,
  Director
• Daniel Janney,
  Director
• Stephen F Tuck,
  Vice President
• Nancy L Buc,
  Director
• J Tyler Martin,
  VP Clinical Development & CMO
• Christine R Larson,
  VP and Chief Financial Officer
• Capital Partners Lpsymphony...,
  
• Jennifer Lew,
  VP, Finance & PAO
• Mark Kessel,
  Director
• David M Lawrence,
  Director
• Daniel J Levitt,
  VP and Chief Medical Officer
• James Edeerfield Capital Lp...,
  
• Louis C Bock,
  Director
• Jan Leschly,
  Director
• James E Flynn,
  10% owner
• Danielalta California Partn...,
  
• Robert Coffman,
  VP & Chief Scientific Officer
• David F Novack,
  President & COO
• Ryan Spencer,
  CEO and Director
• Robert Janssen,
  SVP and CMO
• Kelly Mac Donald,
  SVP and CFO
• Justin Burgess,
  VP Finance & CAO
• Andrew A. F. Hack,